Sahajanand Medical Technologies Q2 Results 2026: PAT ₹26 Cr
Q2 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹373Cr
- Net profit
- ₹26Cr
- Margin
- 17.6%
Guidance rank: #8 of 13 in Healthcare Equipment & Supplies
See the sector's top 10 — free with your mobile number.
What the Q2 FY27 call signalled
2 of 3 strong
The short version
Revenue is expected to grow at mid to high teens in constant currency terms for current and next year. Revenue growth expected in mid to high teens in constant currency for FY 2027 and FY 2028.
From Sahajanand Medical Technologies Ltd's Q2 FY27 earnings-call transcript · updated 10 Nov 2026.
How did Sahajanand Medical Technologies' revenue grow in the September 2026 quarter?
- Revenue is expected to grow at mid to high teens in constant currency terms for current and next year.
- Growth will come from both vascular intervention and structural heart segments, with structural heart expected to grow faster due to its larger, faster-growing market and smaller current base.
- India business may see a tailwind from new regulations limiting reuse of medical devices, though this will only moderately boost growth.
- International business opportunities exist in adding new product approvals in countries where the company already has presence, accelerating sales ramp-up.
- New product launches such as the Hydra TAVI platform and next-generation valve expected to contribute to revenue growth.
2 more points from Sahajanand Medical Technologies Ltd's call on revenue
Create a free account to keep reading this call
What happened to Sahajanand Medical Technologies' margins in Q2 FY27?
Revenue growth expected in mid to high teens in constant currency for FY 2027 and FY 2028.
Locked: what Sahajanand Medical Technologies Ltd said on margins
Also locked on this page: fundraising
Free account, 30 seconds. No card needed.
What capex is Sahajanand Medical Technologies planning?
- Capex guidance for FY 2027 and FY 2028 is approximately INR 70 crores per year.
- Around INR 44 crores have already been spent in H1 FY 2027.
- Capex is focused on three main areas:
- Vertical integration to bring outsourced processes in-house.
- Automation improvements.
- Maintenance capex for the legacy plant in Sachin.
- A small part of the capex is allocated to capacity enhancement.
- Current capacity is adequate for at least 1.5 years; future capacity additions will be incremental.
2 more points from Sahajanand Medical Technologies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Sahajanand Medical Technologies raising money or cutting debt?
Borrowings stand at INR 300 crores with net debt around INR 223 crores, showing manageable leverage (about…
Locked: what Sahajanand Medical Technologies Ltd said on fundraising
Also locked on this page: margins
Free account, 30 seconds. No card needed.
How big is Sahajanand Medical Technologies' order book?
2 more points from Sahajanand Medical Technologies Ltd's call on order book
Create a free account to keep reading this call
Sahajanand Medical Technologies Ltd — Quarterly revenue & net profit
Sahajanand Medical Technologies Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 373 |
| Operating profit (EBITDA) | 66 |
| Operating margin | 17.6% |
| Profit before tax | 40 |
| Net profit (PAT) | 26 |
| EPS (₹) | 2.63 |
Source: Sahajanand Medical Technologies Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹373 Cr, net profit ₹26 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Healthcare Equipment & Supplies
- Poly Medicure Q2 FY27 results
- Molbio Diagnosti Q2 FY27 results
- Tarsons Products Q2 FY27 results
- Laxmi Dental Q2 FY27 results
- Vasa Denticity Q2 FY27 results
- OSEL Devices Q2 FY27 results
- Nureca Q2 FY27 results
- Vaidya Sane Q2 FY27 results
All Q2 FY27 results | Healthcare Equipment & Supplies rankings
Continue your research
Others in Healthcare Equipment & Supplies this season
- OSEL Devices (Q2 FY27)
31.8% increase ((19,363.37 . Key results statement takeaways from OSEL Devices Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Tarsons Products (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026: ₹1,002.32 million (Standalone), ₹1,236.50 million (Consolidated). Key investor presentation ta
- Avience Biomedicals (Q2 FY27)
430.93 Lakhs or approximately 16.07%. Key results statement takeaways from Avience Biomedicals Ltd's Q2 FY27 results statement — and how it ranks against sector
- Vasa Denticity (Q2 FY27)
Growth levers prioritize increasing average revenue per user (ARPU) rather than just increasing order volume or average order value (AOV), which still has room…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Poly MedicureGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sahajanand Medical Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sahajanand Medical Technologies Ltd Q2 FY27 results?
Revenue is expected to grow at mid to high teens in constant currency terms for current and next year. Revenue growth expected in mid to high teens in constant currency for FY 2027 and FY 2028.
What is Sahajanand Medical Technologies Ltd share price analysis?
Sahajanand Medical Technologies Ltd currently shows a below-average growth signal. The stock trades at a P/E of 69.8 with a market cap of ₹5,010 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sahajanand Medical Technologies Ltd planning capital expenditure?
Capex guidance for FY 2027 and FY 2028 is approximately INR 70 crores per year.
Keep Sahajanand Medical Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
